What Is Medroxyprogesterone Acetate?

Medroxyprogesterone acetate, commonly known by the brand name Depo-Provera, is a synthetic progestogen used most widely as an injectable contraceptive but also prescribed for endometriosis, abnormal uterine bleeding, certain cancers, and appetite loss in advanced illness. It works by mimicking progesterone closely enough to suppress ovulation, thin the uterine lining, and thicken cervical mucus. Because a single shot provides roughly three months of pregnancy prevention, it became one of the most popular long-acting reversible methods worldwide. But the drug’s reach across body systems, from bone density to brain tumor risk, has kept researchers busy for decades and given users more to weigh than they might expect from a contraceptive.

How It Prevents Pregnancy

MPA’s contraceptive power comes primarily from shutting down the hormonal signals that trigger ovulation. Injected into muscle (150 mg) or under the skin (104 mg), the drug creates a sustained blood level high enough to keep the brain from releasing the surge of hormones needed for an egg to mature and release. A study tracking subcutaneous depot MPA found that no participants ovulated when blood concentrations of MPA exceeded 0.2 ng/mL, and the median concentration at which ovulation finally returned was just 0.07 ng/mL, a level so low it takes months to reach after the last injection.¹ The subcutaneous version delivers about 30 percent less drug than the intramuscular shot yet suppresses ovulation just as reliably for the full 13-week dosing interval.²

Alongside ovulation suppression, MPA thins the endometrium so that even if an egg were somehow fertilized, implantation would be unlikely. It also makes cervical mucus thicker and harder for sperm to penetrate. These backup mechanisms contribute to the drug’s very low typical-use failure rate, making it one of the more forgiving contraceptive methods for people who might occasionally be late for a scheduled injection.

How Long It Takes to Get Pregnant Afterward

The single biggest practical complaint about depot MPA is the unpredictable delay in fertility after stopping. Because the drug slowly leaches out of the injection site over many weeks, you cannot simply “turn it off.” A narrative review of the evidence found that the median time from last injection to ovulation was about seven months for the subcutaneous formulation and about six months for the intramuscular version.³ Individual variation is wide: the fastest return recorded was roughly three and a half months after the last subcutaneous shot, while the slowest was nearly a year.⁴ By the end of 12 months after the last injection, about 95 to 97 percent of users had ovulated regardless of formulation.

This delay does not mean permanent harm to fertility. It reflects the time it takes for the body to clear the drug depot. But for someone hoping to conceive soon, the waiting period can be frustrating. Clinicians generally advise switching to a shorter-acting method at least a year before a planned pregnancy to avoid that limbo.

Weight and Body Composition Changes

Weight gain is one of the most commonly reported side effects of depot MPA, and the data back up the concern. In a controlled study comparing depot MPA users with women using no hormonal contraception, users gained an average of about 6 kg (roughly 13 pounds) over 30 months, while the control group’s weight stayed essentially flat.⁵ The gain was not merely water retention or lean mass: fat mass increased by about 24 percent, and the distribution of fat shifted toward the midsection. Central fat gain matters because it is more closely linked to metabolic risks than fat stored in the hips or thighs.

Not everyone gains weight on depot MPA. Some users see little change, and early weight trajectories in the first six months seem to predict who will go on to gain the most. If you notice rapid weight gain in the first few months, discussing alternative methods with a provider is reasonable rather than assuming the trend will level off.

Bone Density Loss and Recovery

MPA suppresses estrogen production as part of how it prevents ovulation, and estrogen is critical for maintaining bone density. Long-term users can lose a meaningful amount of bone mineral. Earlier studies reported an average deficit of about 7.5 percent in the lumbar spine among long-term users.⁶ This prompted the FDA to add a black-box warning in 2004 advising against use beyond two years unless other methods are inadequate.

The good news is that bone density recovers after stopping. A review of the evidence found that bone density consistently trended back toward baseline once the drug was discontinued, with recovery visible as early as 24 weeks and continuing over years of follow-up. Past users eventually showed bone density similar to that of women who had never used the drug.⁷ In the BMJ study, women who stopped depot MPA gained back an average of 6.4 percent of spine density over two years, suggesting the earlier 7.5 percent loss is nearly fully reversible.⁸ One study tracking first-time users for 48 months after they quit showed that the longest users remained about 3 to 5 percent below their original baseline at the hip 18 months post-discontinuation, with recovery still ongoing.⁹

The clinical upshot: for most young users, the bone-density dip is temporary and unlikely to raise fracture risk later in life. The concern is greater for adolescents who have not yet reached peak bone mass and for older premenopausal women who have fewer years of estrogen-driven recovery ahead. In these groups, the two-year advisory carries more practical weight.

Blood Clot Risk

Combined hormonal contraceptives containing estrogen are well known to raise the risk of venous blood clots. The picture with progestogen-only methods like depot MPA is murkier, but accumulating evidence suggests the drug is not entirely innocent. A Dutch study found that injectable depot MPA was associated with roughly a 3.6-fold increase in deep vein thrombosis compared to women not using hormonal contraception.¹⁰ A meta-analysis of progestogen-only contraceptive users estimated the relative risk of a clot at about 2.7 for injectable progestin users, though the authors noted the association needed further study.¹¹

A systematic review added nuance: the clot risk with depot MPA appeared higher among smokers and women carrying certain inherited clotting mutations, although the numbers were too small to draw firm boundaries around how much higher.¹² In absolute terms, venous thromboembolism is rare in young women, so even a threefold increase in relative risk translates to a small absolute number of extra clots per year. But if you already have a clotting disorder or smoke, this is a factor worth discussing with a provider.

Breast Cancer and the Women’s Health Initiative

Much of what the public knows about MPA and breast cancer comes from the Women’s Health Initiative (WHI), a large randomized trial in which postmenopausal women received either daily conjugated estrogens plus 2.5 mg of oral MPA or a placebo. During the first two years, the hormone group actually had fewer breast cancer diagnoses. After that, the numbers climbed, and by the end of the roughly five-and-a-half-year intervention period, the combined therapy group had a significantly elevated breast cancer rate.¹³ An extended analysis confirmed this time-dependent pattern: risk was below baseline early on, then rose throughout the intervention phase and reached statistical significance.¹⁴

Two important caveats: the WHI studied oral MPA combined with estrogen in older postmenopausal women, a very different population and dose route from a young woman getting a quarterly contraceptive injection. And the increased risk dropped quickly after women stopped taking the combined therapy. Still, these findings drove a major shift away from long-term combined hormone therapy for menopause management and remain part of why clinicians discuss progestogen type carefully when prescribing hormone replacement.

Meningioma Risk

One of the more surprising findings in recent years is a link between injectable MPA and meningiomas, the mostly benign but sometimes problematic brain tumors that grow from the membranes surrounding the brain. A large French case-control study found that injectable MPA carried an odds ratio of about 5.5 for meningioma, an association driven by use lasting a year or more.¹⁵ A U.S. study using matched groups reported a roughly 2.4-fold increased risk of meningioma diagnosis among depot MPA users.¹⁶ And a third study analyzing over 117,000 meningioma cases found that injection MPA (but not oral MPA) was associated with a 53 percent increase in odds of meningioma, particularly cerebral meningiomas, with risk growing with longer duration of use.¹⁷

The absolute risk remains very low. The U.S. study calculated a “number needed to harm” of about 1,152 patients, meaning you would need to treat more than a thousand women with depot MPA before one extra meningioma diagnosis appeared.¹⁸ Meningiomas are almost always slow-growing and treatable. But the consistency across independent datasets, and the dose-duration relationship, has led French regulators to restrict certain progestogen prescriptions, and it is something users of long-term injectable MPA should be aware of.

HIV Susceptibility Concerns

In regions with high HIV prevalence, especially sub-Saharan Africa, depot MPA is also the most widely used hormonal contraceptive. This overlap has driven intense research into whether the drug affects HIV risk. The concern is biological, not behavioral. Animal studies have shown that MPA can impair vaginal epithelial barrier integrity, making it easier for pathogens to cross into underlying tissue.¹⁹ In human tissue studies, a single depot MPA injection significantly increased the number of CCR5-bearing immune cells in vaginal tissue, which are the cells HIV preferentially targets.²⁰

More recently, a study of cervical secretions found that endocervical samples collected after depot MPA treatment promoted HIV infectivity in lab assays compared to pre-treatment samples, with decreased levels of the natural HIV-blocking molecule RANTES and increased presence of HIV-susceptible T cells.²¹ The large ECHO trial (Evidence for Contraceptive Options and HIV Outcomes), which compared depot MPA head-to-head with a copper IUD and a levonorgestrel implant in African women, found no statistically significant difference in HIV acquisition rates between the three groups, which somewhat calmed the debate. But the biological plausibility remains, and public health authorities in high-prevalence settings continue to recommend that depot MPA users also use condoms.

Uses Beyond Contraception

MPA has a surprisingly wide range of non-contraceptive applications, reflecting the drug’s ability to interact with progesterone, glucocorticoid, and even androgen-related pathways.

Endometriosis Pain

Depot MPA is a well-established option for managing endometriosis-related pelvic pain. In a trial comparing it to an oral contraceptive combined with low-dose danazol, about 73 percent of women in the depot MPA group reported satisfaction after a year, and both symptom types improved significantly, with less dysmenorrhea in the depot MPA group.²² A randomized trial pitting depot MPA against a levonorgestrel intrauterine system for long-term maintenance after surgical treatment found that both therapies controlled symptoms and recurrence.²³

Cancer Treatment and Appetite Stimulation

High-dose oral MPA has a distinct role in oncology. In young women with early-stage endometrial cancer or its precursor (atypical hyperplasia) who wish to preserve fertility, daily oral MPA at 600 mg produced complete responses in 55 percent of cancer cases and 82 percent of hyperplasia cases in a prospective trial.²⁴ This is not a replacement for surgery in most patients, but it offers a window for pregnancy before definitive treatment.

Separately, MPA is one of only two progestational drugs approved in Europe for cancer-related anorexia and cachexia, the devastating wasting syndrome that accompanies advanced malignancies. A systematic review of randomized trials found that high-dose progestins improved appetite about fourfold and increased body weight about two-and-a-half-fold compared to placebo.²⁵ A placebo-controlled trial confirmed a significant appetite improvement starting by week three and persisting through week six, with supportive biomarker changes, though the gain was in fat rather than muscle and did not translate to improved performance status or energy.²⁶ A review of MPA specifically for cachexia reached the same conclusion: weight gain was real but came from fat, not lean tissue.²⁷

Menstrual Suppression in Transgender Men

Depot MPA is sometimes used alongside testosterone in transgender men or transmasculine adolescents to accelerate cessation of menstruation. In a cohort study of adolescent and young adult transgender males, those starting testosterone alongside depot MPA had a median time to cessation of menses of about 168 days, comparable to the group using an oral progestin.²⁸ This application is valued because ongoing menstruation can be a significant source of gender dysphoria, and depot MPA can bridge the gap while testosterone gradually achieves full menstrual suppression on its own.

MPA Is Not the Same as Natural Progesterone

MPA is often lumped together with progesterone in casual conversation, but the two behave quite differently in the body. MPA binds tightly to both the progesterone receptor and the glucocorticoid receptor, a dual affinity that natural progesterone does not share as strongly.²⁹ The glucocorticoid activity helps explain some of MPA’s broader effects, including immune modulation and metabolic changes, and may also underlie some of its side effects. The strength of this glucocorticoid binding even varies by species: in rabbits, MPA competes for glucocorticoid receptors about as well as the body’s own cortisol, while in rats it is far weaker.³⁰

This distinction matters clinically. Research on brain-derived neurotrophic factor (BDNF), a protein important for brain cell health, found that natural progesterone boosted BDNF levels in brain tissue while MPA did not. The authors emphasized that not all progestins have equivalent effects on the brain and that the choice of progestogen in hormone therapy formulations could meaningfully influence neurological outcomes. This finding fed into the broader push, especially after the WHI, to move postmenopausal hormone therapy toward micronized progesterone and away from MPA when a progestogen is needed to protect the uterine lining.

Pregnancy Safety

Given that depot MPA can take months to clear, some women become pregnant while residual drug is still circulating. A study of 366 pregnancies exposed to MPA in early gestation found a congenital abnormality rate of about 4.1 percent, statistically indistinguishable from the 3.5 percent rate in unexposed pregnancies. The authors concluded that MPA posed no measurable teratogenic risk and did not appear to selectively preserve abnormal pregnancies that would otherwise miscarry.³¹

Animal data are more mixed. In mice and rats, even high doses of MPA did not produce fetal malformations, but in rabbits, moderate doses caused cleft palate at rates ranging from 6 to 42 percent depending on the dose.³² The rabbit finding ties back to the species difference in glucocorticoid receptor binding: MPA acts much more like a glucocorticoid in rabbits, and glucocorticoid excess is a known cause of cleft palate in that species.³³ In humans, the reassuring epidemiological data carry more weight than rabbit findings, and current evidence does not support the once-common worry about birth defects from early gestational MPA exposure.

MPA in the Environment

Because millions of people use MPA worldwide, the drug inevitably enters waterways through sewage and agricultural runoff. Researchers have detected it in surface water at concentrations in the low nanograms-per-liter range, and even at those trace levels the effects on aquatic life are measurable. Chronic exposure of zebrafish to environmentally relevant concentrations of MPA skewed sex ratios toward males and disrupted spermatogenesis, confirming that the drug has androgenic activity in fish.³⁴ Another zebrafish study found reproductive impairment and changes in gonad tissue at concentrations as low as a few nanograms per liter.³⁵

From a bioaccumulation standpoint, MPA appears less concerning than many persistent pollutants. Carp exposed to MPA in the lab accumulated the drug primarily in the liver and brain, with bioconcentration factors between about 4 and 38, well below the thresholds regulators use to flag a compound as bioaccumulative.³⁶ The risk to fish populations is more about continuous low-level exposure in polluted waterways than about the drug building up in tissue over time.

Veterinary Use

MPA is not exclusively a human drug. Veterinarians use it to suppress estrus (heat cycles) in cats and dogs, particularly in settings where surgical spaying is unavailable or unaffordable. A study of female cats given a single 50 mg injection of MPA found significant ovarian shrinkage and cessation of follicle development compared to untreated controls, though 3 out of 10 treated cats developed follicular cysts.³⁷ Veterinary use shares many of the same trade-offs as human use: effective reproductive suppression with potential side effects including mammary tumors, uterine disease, and metabolic changes with long-term administration.